Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Kevin046on Apr 29, 2016 11:26am
188 Views
Post# 24825407

10Q default risk

10Q default riskHere we come another block for investor.

Valeant Says It Could Breach Bond Pact in May If 10-Q Is Delayed

Valeant Pharmaceuticals International Inc. dodged a potential default by filingits 2015 annual report Friday. Now it faces another in two weeks.

The company has until May 16 to submit its first-quarter financial results or risk breaching agreements with bondholders who own $19.5 billion of its debt, it said Friday in the regulatory filing. Valeant reiterated that there’s a risk it may be delayed in filing the results. The company’s bonds fell.

“Under the terms of our senior note indentures, if we do not file the first-quarter 2016 form 10-Q by May 16, 2016, we will be in default,” the company said.

Valeant filed its 2015 annual report Friday, and said it will have no additional financial restatements, is in compliance with its credit agreements, and is under investigation by several state regulatory agencies. The filing met the company’s self-imposed deadline and temporarily satisfies bond and loan holders, who have sent notices of default related to the delayed financials, which were supposed to be submitted in March.

Earlier this month, the company won support from loan holders to make changes to its credit agreement, giving it until July 31 to file its first-quarter financials. It didn’t amend its pact with bondholders at that time.

Valeant’s $3.25 billion of 6.125 percent bonds lost 1.25 cents on the dollar, falling for the first time in more than a week to trade at 84.5 cents on the dollar and yield 8.65 percent at 10:25 a.m. in New York on Friday, according to Trace, the bond-price reporting system of the Financial Industry Regulatory Authority.

Breaching the bond pact will give creditors the right to send Valeant a notice of default, which will start the clock on a 60-day cure period and could shorten the extended deadline of July 31 that it got from loan holders, the company said.

<< Previous
Bullboard Posts
Next >>